Polytherapy with Alpelisib (PIK3CA inhibitor) and Fulvestrant (estrogen receptor antagonist) can improve the survival rates of patients with breast cancer contaning PIK3CA mutations. This evidence concerns the gene ESR1 and breast carcinoma.